<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03202992</url>
  </required_header>
  <id_info>
    <org_study_id>ABI-1968-201</org_study_id>
    <nct_id>NCT03202992</nct_id>
  </id_info>
  <brief_title>Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection</brief_title>
  <official_title>Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Topical ABI-1968 in Subjects With Anal High-Grade Squamous Intraepithelial Lesions (aHSIL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antiva Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Antiva Biosciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the use of ABI-1968, a topical cream, in the treatment of anal
      precancerous lesions in adults with and without human immunodeficiency virus (HIV) infection.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 11, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The study will be conducted in 2 Phases: Part A, up to 5 cohorts of 3 subjects each will receive a single dose of ABI-1968 Topical Cream. In Part B, three cohorts (3 subjects per cohort) will receive multiple doses in 3 ascending dose strengths of ABI-1968 Topical Cream. After completing the ascending dose multiple-dosing cohorts, a multiple-dosing Cohort Expansion group of 30 subjects will be initiated.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of ABI-1968 for the treatment of aHSIL</measure>
    <time_frame>SAD portion is 29 days/MAD portion is 84 days</time_frame>
    <description>Number of participants with Adverse Events related to treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systemic exposure to ABI-1968 Topical Cream following topical application to the anal canal.</measure>
    <time_frame>SAD portion is 29 days/MAD portion is 84 days</time_frame>
    <description>Plasma concentrations of ABI-1968 over time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Histopathology of areas with biopsy-proven disease following single and multiple doses of ABI-1968 Topical Cream.</measure>
    <time_frame>SAD portion is 29 days/MAD portion is 84 days</time_frame>
    <description>Number of subjects with complete and or partial regression of aHSIL by High Resolution Anoscopy (HRA) and histopathology</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Anticipated">57</enrollment>
  <condition>HSIL, High-Grade Squamous Intraepithelial Lesions</condition>
  <condition>Human Papilloma Virus Infection</condition>
  <condition>HIV Infection</condition>
  <condition>Anal Cancer</condition>
  <condition>Anus Neoplasms</condition>
  <arm_group>
    <arm_group_label>Dose 1 -Single Ascending Dose (SAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAD Dose Level 1 of ABI-1968 topical cream applied on Day 1 of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2 -Single Ascending Dose (SAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAD Dose Level 2 of ABI-1968 topical cream applied on Day 1 of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3 -Single Ascending Dose(SAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAD Dose Level 3 of ABI-1968 topical cream applied on Day 1 of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 4 -Single Ascending Dose(SAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAD Dose Level 4 of ABI-1968 topical cream applied on Day 1 of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 5 -Single Ascending Dose(SAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SAD Dose Level 5 of ABI-1968 topical cream applied on Day 1 of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 1 - Multiple Ascending Dose(MAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MAD Dose Level 1 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 2 -Multiple Ascending Dose(MAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MAD Dose Level 2 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 3 -Multiple Ascending Dose(MAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MAD Dose Level 3 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Ascending Dose (MAD) Cohort Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MAD Cohort Expansion of ABI-1968 applied at Day 1, Day 8, Day 15, Day 22 and Day 29</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose 4-Multiple Ascending Dose(MAD)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MAD Dose Level 3 of ABI-1968 topical cream applied at Day 1, Day 8, Day 15, Day 22 and Day 29</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABI-1968</intervention_name>
    <description>Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion</description>
    <arm_group_label>Dose 1 -Single Ascending Dose (SAD)</arm_group_label>
    <arm_group_label>Dose 2 -Single Ascending Dose (SAD)</arm_group_label>
    <arm_group_label>Dose 3 -Single Ascending Dose(SAD)</arm_group_label>
    <arm_group_label>Dose 4 -Single Ascending Dose(SAD)</arm_group_label>
    <arm_group_label>Dose 5 -Single Ascending Dose(SAD)</arm_group_label>
    <arm_group_label>Dose 1 - Multiple Ascending Dose(MAD)</arm_group_label>
    <arm_group_label>Dose 2 -Multiple Ascending Dose(MAD)</arm_group_label>
    <arm_group_label>Dose 3 -Multiple Ascending Dose(MAD)</arm_group_label>
    <arm_group_label>Multiple Ascending Dose (MAD) Cohort Expansion</arm_group_label>
    <arm_group_label>Dose 4-Multiple Ascending Dose(MAD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female or male subjects, at least 27 years old.

          2. Confirmed diagnosis of intra-anal HSIL at least 3 months prior to screening and
             confirmed by histopathology (with p16 positive staining)

          3. Intra-anal HSIL are visible and evaluable by HRA at the time of screening, and no
             lesion(s) is suspicious for invasive cancer.

          4. For HIV-positive subjects, CD4 count must be at least 200/mm3 with undetectable (&lt;50
             copies/mL) viral load within the 3 months prior to enrollment. Subjects must be on a
             stable regimen of antiretroviral drugs for the 3 months prior to enrollment.

        Exclusion Criteria:

          1. Women who are pregnant, plan to become pregnant in the next 3 months, or lactating
             females.

          2. Received topical treatment or ablative procedures for aHSIL in the 6 months prior to
             enrolment.

          3. History of cancer, including anal cancer (with the exception of basal cell or squamous
             cell carcinoma of the skin), or currently undergoing treatment for any skin cancer.

          4. History of genital herpes with &gt; 3 outbreaks per year.

          5. Plan to have excision or ablation of the lesion(s) within 3 months of enrolment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>27 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Operations</last_name>
    <role>Study Chair</role>
    <affiliation>Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may use the contacts provided below. For general i</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Operations</last_name>
    <phone>650-822-1400</phone>
    <email>Clinical@antivabio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clinical Operations</last_name>
      <phone>650-822-1400</phone>
      <email>Clinical@antivabio.com</email>
    </contact>
    <investigator>
      <last_name>Investigator</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Operations</last_name>
      <phone>650-822-1400</phone>
      <email>Clinical@antivabio.com</email>
    </contact>
    <investigator>
      <last_name>Investigator</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Operations</last_name>
      <phone>650-822-1400</phone>
      <email>Clinical@antivabio.com</email>
    </contact>
    <investigator>
      <last_name>Investigator</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Operations</last_name>
      <phone>650-822-1400</phone>
      <email>clinical@antivabio.com</email>
    </contact>
    <investigator>
      <last_name>Investigator</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Operations</last_name>
      <phone>650-822-1400</phone>
      <email>clinical@antivabio.com</email>
    </contact>
    <investigator>
      <last_name>Investigator</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Research Center</name>
      <address>
        <city>Sydney</city>
        <state>Darlinghurst</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Operations</last_name>
      <phone>650-822-1400</phone>
      <email>Clinical@antivabio.com</email>
    </contact>
    <investigator>
      <last_name>Investigator</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2017</study_first_submitted>
  <study_first_submitted_qc>June 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2017</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Papilloma</mesh_term>
    <mesh_term>Anus Neoplasms</mesh_term>
    <mesh_term>Squamous Intraepithelial Lesions of the Cervix</mesh_term>
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

